Roche Holdings AG is developing an oral formulation of the bisphosphonate derivative ibandronic acid as a potential treatment for metastatic bone disease in breast cancer patients; it was filed for this indication in October 2002. Roche and its Japanese subsidiary Chugai Pharmaceutical Co Ltd, in collaboration with GlaxoSmithKline plc, have also developed the formulation for the treatment of osteoporosis.
Gennari, L. (2005). Oral ibandronic acid. IDRUGS, 8(2), 155-169.
Oral ibandronic acid
Gennari L.
2005-01-01
Abstract
Roche Holdings AG is developing an oral formulation of the bisphosphonate derivative ibandronic acid as a potential treatment for metastatic bone disease in breast cancer patients; it was filed for this indication in October 2002. Roche and its Japanese subsidiary Chugai Pharmaceutical Co Ltd, in collaboration with GlaxoSmithKline plc, have also developed the formulation for the treatment of osteoporosis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gennari L (IDrugs Feb 2005).pdf
non disponibili
Tipologia:
Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
116.09 kB
Formato
Adobe PDF
|
116.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/38447
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo